

EP0159089

Publication Title:

A process for preparing an implant material which releases medicines in the body.

Abstract:

Abstract of EP0159089

Implant material for the release of medicine in bone tissues or soft tissues, comprising a medicine and a carrier therefor, composed of calcium sulphate and calcium monohydrogen phosphate. Data supplied from the esp@cenet database
- Worldwide

Courtesy of <http://v3.espacenet.com>

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 85200544.6

(51) Int. Cl.⁴: **A 61 K 9/22**
A 61 L 17/00

(22) Date of filing: 04.04.85

(30) Priority: 04.04.84 NL 8401061

(43) Date of publication of application:
23.10.85 Bulletin 85/43

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: Stichting Biomaterials Science Center, VU,
"BSC-VU"
De Boelelaan 1115
NL-1081 HV Amsterdam(NL)

(72) Inventor: De Groot, Klaas
L. van Wijkplein 6
NL-2101 EL Heemstede(NL)

(74) Representative: Urbanus, Henricus Maria, Ir. et al,
c/o Vereenigde Octroolbureaux Nieuwe Parklaan 107
NL-2587 BP 's-Gravenhage(NL)

(54) A process for preparing an implant material which releases medicines in the body.

(57) Implant material for the release of medicine in bone tissues or soft tissues, comprising a medicine and a carrier therefor, composed of calcium sulphate and calcium monohydrogen phosphate.

A process for preparing an implant material which releases medicines in the body.

This invention relates to a system which after implantation releases a medicine to its surroundings, and which during the process of release is dissolved in full.

It can be inferred from an article by Wahling et al. (The release
5 of gentamycin from polymethylmethacrylate beads, J. Bone Joint Surg.
Br. Vol., 1978, 60, 270) that a two-component system consisting of beads
of polymethylmethacrylate ("bone cement") in which the antibiotic genta-
mycin is dissolved is capable of successfully treating osteomyelitis. One
disadvantage is that after the release of the antibiotic the beads of
10 bone cement must be surgically removed from the bone. In the literature,
therefore, certain methods are indicated of using, instead of the non-
resorbing bone cement, a material that is dissolved in the body itself,
so that surgical removal is unnecessary.

A first method is the use of beta-whitlockite instead of bone
15 cement. Beta-whitlockite (chemical formula $\text{Ca}_3(\text{PO}_4)_2$) is, under certain
conditions, more or less soluble. The biological dissolving process
depends on the way in which the subject product has been sintered.
(Sintering is a process - see a Chapter by K. de Groot in the book
"Biocompatibility of Clinical Implant Materials", Editor D.F. Williams,
20 C.R.C. Press, Boca Raton, USA, 1981, 199 - 224 - the principle of which
is that, by heating, powder particles are cemented together via solid-
state diffusion, so that from a powder, a solid body is formed). The
rate of dissolution is promoted by ensuring that the powder particles
are only connected together by means of small "necks". Eittenmuller et
25 al. (see his paper entitled: Resorbierbare Antibiotik/Antiseptische
TCP-keramik zur lokalen Behandlung der Osteomyelitis, L. Koelner Workshop
über Hydroxylkeramik, Cologne, December 7, 1983) have used this beta-
whitlockite (also referred to as beta-TCP or β -TCP) in a highly porous
form as a carrier for an antibiotic, instead of bone cement.

30 A second method is the use of calcium sulphate (Plaster of Paris).
Varlet et al., in the article "Billes de platre de Paris aux antibiotique
dans le traitement de l'infection osseuse", in "Revue de Chirurgie
Orthopedique", 1983, 69, 239 - 244, have indicated and shown that gypsum,

- 2 -

too, can function as a biologically soluble bead. Their method is predicated on gypsum being made up with the medicine to form a solid final product (by adding water), which like Eitzenmuller's TCP has a highly porous composition. Other methods are not based on ceramic starting materials, and accordingly fall outside the scope of the present patent application.

Characteristic of both methods is that the medicine ("antibiotic") is released by diffusion, whereafter the remaining implant (the remaining component) is resorbed, so that the surgical removal of the beads is unnecessary. (It follows that the release of the medicine is not determined by the rate of biodegradation of the implant system).

Both methods, however, have certain disadvantages. Beta-TCP has the disadvantage that the dissolving process may have adverse side-effects. The cause is as follows. After being implanted, a porous beta-TCP product, on account of the loose bond between the sintered particles ("weak necks") disintegrates into loose particles, which in turn are carried off by macrophages to neighbouring lymph glands. Depending on the weakness of the bond between the sintered particles, the dissolving process which is thus effected is taking place at a faster or slower rate. (Non-porous beta-whitlockite is hardly resorbed). In certain cases the particles carried off are not intracellularly dissolved before the lymph glands are reached, so that, in that case, the lymph glands are filled with calcium phosphate particles. If no macrophages are present, or not enough, particles are accumulated around the implant, whereby further release is adversely affected. A second disadvantage of beta-TCP is that the dissolving process is biologically determined owing to the essential role of macrophages, so that there is no certainty as to the eventual disappearance of the implant.

Calcium sulphate, too, has a disadvantage: its rate of dissolution is so high that the implant is not always replaced by bone tissue, which may leave a void (Frame, J. Dent., 3, 177, 1975). One advantage, compared with beta-whitlockite, is that the dissolving process is a truly physico-chemical, and hence predictable one.

The present invention provides a system which (1) unlike the beta-whitlockite described earlier, is dissolved not via disintegration

into small particles, and hence without involving macrophagic removal; and (2) is not dissolved as fast as gypsum, so that bone voids may be left.

The invention is characterized by being a system comprising a
5 matrix of a mixture of CaSO_4 and CaHPO_4 , in variable proportions, produced by heating powders of CaSO_4 and CaHPO_4 together to the melting point of CaHPO_4 , i.e., about 700°C , for some minutes. As this mixture has a solubility which, on the one hand, is intermediate that of CaSO_4 and that of CaHPO_4 (see the above article by K. de Groot) and, on the other
10 hand, is many times higher than that of beta-whitlockite, it is thus achieved that the dissolving process (1) can be varied in rate, and (2) is not brought about via particles to be carried off by macrophages. To the matrix, heated to form a microporous mass, the desired medicine can be added by means of impregnation.

C L A I M S

1. Implant material for the release of medicine in bone tissues or soft tissues, comprising a medicine and a carrier therefor, characterized in that the carrier is composed of calcium sulphate and calcium monohydrogen phosphate.
- 5 2. A process for producing an implant material for the release of medicine, comprising a medicine and a carrier therefor, characterized by heating a mixture of calcium sulphate and calcium monohydrogen phosphate to form a microporous mass, and incorporating a medicine therein by impregnation.



European Patent
Office

EUROPEAN SEARCH REPORT

0159089
Application number

EP 85 20 0544

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	EP-A-0 087 662 (MERCK PATENT GmbH) * Page 4, line 7 - page 6, line 17 *	1-2	A 61 K 9/22 A 61 L 17/00
A	GB-A-2 093 348 (LEO PHARMACEUTICAL PROD. LTD.) * Page 4, lines 24-105 *	1-2	
A	GB-A- 630 439 (ETHAN ALLAN BROWN) * Page 2, line 108 - page 3, line 34 *	1-2	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			A 61 K A 61 L
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 11-07-1985	Examiner BRINKMANN C.
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			